Primary Stability of the Implants

The goal of this randomized clinical trial is to compare the primary stability of double-thread and triple-thread dental implant designs in patients requiring implant placement in the posterior maxilla. The main question it aims to answer is whether implant thread design influences primary implant stability in the posterior maxilla. Participants will be randomly assigned to one of two groups. Group A will receive a double-thread dental implant, while Group B will receive a triple-thread dental implant. Primary implant stability will be assessed at the time of implant placement using insertion torque and resonance frequency analysis (ISQ).implant stability using ISQ will also be evaluated at 3 months

use of Thymoquinone hydrogel with bone graft in comparison to bone graft only around immediate implant-this hydrogel fill the jumping zone in comparison to using hydrogel bone graft only to increase primary stability and enhance osseointegration

Based on the scientific evidence, the relevance of this subject, we consider this study to be justified, the general or specific objective of which is as follows: 'To evaluate the effect of the administration of Osteoimplant© and Osteoimplant Complex© as a food supplement in obtaining implant stability and in the healing of dental implant surgery'. As secondary objectives, we will also evaluate the effect of Osteoimplant© and Osteoimplant Complex© on pain, postoperative inflammation and soft tissue healing. The sample will consist of 60 patients. The sample will be randomly divided into 2 groups using a randomisation table generated by a statistical programme. For blinding, neither the patient nor the operator shall be aware of the group to which each patient belongs. To ensure blinding, medication will be delivered in sealed, opaque envelopes. Patients shall be assigned to one of the following groups: * Group I: 30 patients prescribed to take Osteoimplant Complex© on the following schedule: 2 tablets per day starting 5 days before implant placement and 1 tablet per day of Osteimplant© for 2 months after implant placement. * Group II: 30 patients who were prescribed placebo with the following regimen: 2 tablets per day starting 5 days before implant placement and 1 tablet per day for 2 months after implant placement.